Ganoderma lucidum is a favorite for use in liver protection. There is a study of patients suffering from hepatitis B and elevated liver enzymes (SGOT/SGPT) and bilirubin, patients where they were given ganoderma lucidum for three months. Within the first month, significant reduction in SGOT and SGPT were seen, and three months later all patients were within a healthy state.
Ganoderma is a very important supplement for those who have liver cancer as it enhances the liver's detoxification by improving liver function and stimulating the regeneration of liver cells. The cancer killing agents in Ganoderma are the polysaccharides and Germanium. The polyshaccharide fraction of Ganoderma is largely responsible for its anti-tumor efficacy.
Ganoderma is a very powrful cancer killer and is used in treatment such as supplementation to reduce side-effects during chemotherapy or radiotherapy, prolonging survival and minimizing metastasis of the cancer, improving quality of consumer's lives, and to prevent occurrence or recurrence.
Ganoderma can be used as a supplement during chemotherapy and radiotherapy to reduce side-effects such as fatigue, loss of appetite, hair loss, bone marrow suppression and the risk of infection. It can also reduce the side effects and eliminate the pain during chemotherapy and radiotherapy, particularly terminal cancer patients can prolong their lives and improve their living quality by consuming Ganoderma on a regular basis.
There has been an incredible breakthrough in the way you can actually ingest 100% organic ganoderma every day without seeing, tasting or smelling the herb.
Do you drink coffee, tea, or hot chocolate? What about taking a shower or brushing your teeth? You now can have 100% organic ganoderma be apart of your daily routine and start living a healthier life today at the click of a button. Find it on this website: www.christopherbinns.organogold.com
Would you like to be a distributor of this amazing herb in its ingeniously habitual form? contact misterpherbinns@yahoo.com for more info.
No comments:
Post a Comment